PAPER Claudino PA, Bueno NB, Piloneto S, Halaiko D, Azevedo de Sousa LP, Barroso Jara Maia CH, Netto BD

Consumption of ultra-processed foods and risk for Alzheimer's disease: a systematic review.

Front Nutr. 2023;10:1288749. Epub 2024 Jan 15 PubMed: 38288062

PAPER Fu J, Qin Y, Xiao L, Dai X

Causal relationship between gut microflora and dementia: a Mendelian randomization study.

Front Microbiol. 2023;14:1306048. Epub 2024 Jan 15 PubMed: 38287957

PAPER Tapella L, Dematteis G, La Vitola P, Leva S, Tonelli E, Raddi M, Delconti M, Dacomo L, La Macchia A, Murari E, Talmon M, Malecka J, Chrostek G, Grilli M, Colombo L, Salmona M, Forloni G, Genazzani AA, Balducci C, Lim D

Genetic deletion of astrocytic calcineurin B1 prevents cognitive impairment and neuropathology development in acute and chronic mouse models of Alzheimer's disease.

Glia. 2024 May;72(5):899-915. Epub 2024 Jan 30 PubMed: 38288580

PAPER Ding Q, Lamberts J, Konieczny AM, Bringedahl TB, Torres Garcia KY

Association of Autoimmune Disorders and Disease-modifying Antirheumatic Drugs: (DMARDs) with the Risk of Alzheimer's and/or Dementia: A Population Study Using Medicare Beneficiary Data.

Curr Alzheimer Res. 2023;20(10):725-737. PubMed: 38288824

PAPER Wenger K, Viode A, Kumar M, Steen H, Steen JA

Quantitative profiling of posttranslational modifications of pathological tau via sarkosyl fractionation and mass spectrometry.

Nat Protoc. 2024 Apr;19(4):1235-1251. Epub 2024 Jan 30 PubMed: 38291250

YuHong Fu

Marisa Vizuete

Spain

Peter Nelson on In FTD, TMEM106b Fibrils Tip TDP-43 Dysfunction into Overdrive

COMMENT Genetic variation at the TMEM106B locus is a massively under-appreciated risk factor for dementia, with a large impact on public health. TMEM106B variance was identified as a genetic modifier of dementia risk in the context of FTLD/FTD, as re-emphasized w

In FTD, TMEM106b Fibrils Tip TDP-43 Dysfunction into Overdrive

RESEARCH NEWS 2024-01-30 Research News Variants in the TMEM106b gene influence the risk and severity of frontotemporal dementia, but how? A study published January 17 in Science Translational Medicine suggests that the answer comes down to the lysosomal protein’s propensity to tw

Amy Goetsch

Lilly USA
Minnetonka, United States

Laura McEntire

Alzheimer's Association
Fort Worth, United States

Mike Miguel Pappolla on Brain of Woman Who Died on Leqembi Shows Worst-Case Scenario

COMMENT As we continue to struggle with the challenges of treating CAA-RI, the potential role of immunosuppressive therapy emerges as a critical area of focus. For high-risk groups undergoing treatment with Leqembi, particularly those identified as probable cases

PAPER Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, Bütikofer L, Seitz M, Reichenbach S

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Lancet. 2016 May 7;387(10031):1921-7. Epub 2016 Mar 4 PubMed: 26952547

Mark Rafferty

United States

Dementias Platform UK: Translation 2024

CONFERENCE 2024-04-18 00:00:00-2024-04-19 00:00:00 London, U.K. 18 &#x2013 19 April 2024 View Conference Website 0